DD - DuPont de Nemours, Inc.

NYSE - NYSE Delayed Price. Currency in USD
66.12
+0.95 (+1.46%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close65.17
Open65.66
Bid65.88 x 800
Ask66.40 x 900
Day's Range64.97 - 66.77
52 Week Range17.84 - 102.38
Volume2,860,464
Avg. Volume4,506,546
Market Cap49.291B
Beta (3Y Monthly)1.21
PE Ratio (TTM)54.83
EPS (TTM)1.21
Earnings DateNov 1, 2019 - Nov 5, 2019
Forward Dividend & Yield3.00 (4.60%)
Ex-Dividend Date2019-07-30
1y Target Est84.96
Trade prices are not sourced from all markets
  • After the DowDuPont Split: An Investor’s Guide to the 3 New Companies
    Motley Fool

    After the DowDuPont Split: An Investor’s Guide to the 3 New Companies

    The chemical industry heavyweight is gone, and DuPont and Dow are officially back -- but very different. Here's how to keep track of the new companies.

  • Thomson Reuters StreetEvents

    Edited Transcript of DD.N earnings conference call or presentation 1-Aug-19 12:00pm GMT

    Q2 2019 Dupont De Nemours Inc Earnings Call

  • How Tesla has Become Most Profitable Short Bet at $2.75 Billion
    Investopedia

    How Tesla has Become Most Profitable Short Bet at $2.75 Billion

    Tesla short sellers may reap even bigger profits if CEO Musk fails to revive the electric car company.

  • Benzinga

    Jim Cramer Gives His Opinion On Alibaba, Lockheed Martin And More

    On CNBC's "Mad Money Lightning Round,"  Jim Cramer said he is not against owning Alibaba Group Holding Ltd - ADR (NYSE: BABA ). He thinks that business is quite good. Cramer likes Automatic Data ...

  • DuPont Falls 4%
    Investing.com

    DuPont Falls 4%

    Investing.com - DuPont (NYSE:DD) fell by 4.03% to trade at $65.71 by 14:33 (18:33 GMT) on Wednesday on the NYSE exchange.

  • DuPont Considers Sale of Biosciences Unit That Could Fetch $20 Billion
    Bloomberg

    DuPont Considers Sale of Biosciences Unit That Could Fetch $20 Billion

    (Bloomberg) -- The serial dealmaker running DuPont de Nemours Inc. is gearing up for another $20 billion-plus divestment that could become one of the chemical industry’s biggest transactions this year.DuPont Chairman Ed Breen is considering unloading the company’s nutrition and biosciences business, one of its fastest-growing divisions, according to people familiar with the matter. A sale would extend a dramatic overhaul of DuPont’s portfolio as it looks to salvage shareholder value in the face of slowing markets and the U.S.-China trade war that has crimped growth.DuPont’s current incarnation resulted from the breakup of DowDuPont, the chemical giant created in a 2017 deal that was the chemical industry’s biggest merger of all time. It’s since spun off its Corteva Inc. agriculture business, which is now worth $22.5 billion as a standalone entity.A divestment of the nutrition and biosciences division -- which makes food additives and ingredients -- could help unlock more value for Wilmington, Delaware-based DuPont, which had a market capitalization of $51 billion at Tuesday’s close. The company is now working with advisers to evaluate options for the unit including a potential sale or spinoff, the people said. More SpinoffsIt is also considering a so-called Reverse Morris Trust, a merger with another company structured to be tax-free. Logical partners for that kind of deal could include Royal DSM NV, Kerry Group Plc, Givaudan SA and International Flavors & Fragrances Inc., the people said. Some of the suitors have lined up advisers for potential bids, the people said.The nutrition and biosciences unit, which has more than 10,000 employees, specializes in products from sweeteners and emulsifiers to dairy cultures and dietary fibers. DuPont has seen particular strength in areas such as plant-based meats and probiotics.The division could be worth at least $20 billion on its own based on rivals’ trading multiples, the people said. Its revenue rose 14% last year to $6.8 billion, making it DuPont’s fastest-growing business after the industrial intermediates and infrastructure division, according to data compiled by Bloomberg.M&A PlaybookDuPont is in the early stages of the review and may opt to not proceed with a divestiture, the people said. It also hasn’t started holding any formal talks with potential suitors yet, they said. Representatives for DuPont and International Flavors declined to comment. Representatives for DSM, Kerry and Givaudan weren’t immediately available for comment.Analysts have suggested DuPont’s chairman may run a similar playbook for the company as he did when breaking apart DowDuPont. A serial dealmaker, Breen also engineered the breakup of Tyco International Plc. DuPont has already earmarked for sale six “non-core” businesses with a combined $2 billion in annual sales, including a unit that makes solar-panel materials, and Breen has said he would consider more moves.DuPont has four major divisions big enough to stand on their own, and it could sell or spin major business units including nutrition or electronics and imaging, Breen said at an industry conference in May. For tax reasons, DuPont can’t begin holding any talks with other companies until after the two-year anniversary of the combination that created its predecessor, he said. Dow and DuPont completed their merger on Aug. 31, 2017.If DuPont succeeds in divesting the nutrition division, it would be left with businesses focused on materials for industries such as transportation, electronics and construction.\--With assistance from Myriam Balezou and Aaron Kirchfeld.To contact the reporters on this story: Kiel Porter in Chicago at kporter17@bloomberg.net;Dinesh Nair in London at dnair5@bloomberg.net;Richard Clough in New York at rclough9@bloomberg.netTo contact the editors responsible for this story: Brendan Case at bcase4@bloomberg.net, ;Liana Baker at lbaker75@bloomberg.net, Ben Scent, Amy ThomsonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Reuters

    UPDATE 1-DuPont considers sale of nutrition and biosciences unit - Bloomberg

    Industrial materials maker DuPont is considering a sale of its nutrition and biosciences unit, Bloomberg reported on Tuesday, citing people familiar with the matter. The unit, which supplies everything from soy-based food ingredients to tablet binders, could be worth at least $20 billion as a standalone entity, Bloomberg said https://www.bloomberg.com/news/articles/2019-08-06/dupont-is-said-to-weigh-divestiture-of-nutrition-and-biosciences. DuPont declined to comment on the unit's divestiture.

  • DuPont Rises 4%
    Investing.com

    DuPont Rises 4%

    Investing.com - DuPont (NYSE:DD) rose by 4.13% to trade at $68.79 by 14:25 (18:25 GMT) on Tuesday on the NYSE exchange.

  • Local companies impacted by trade war-fueled stock market decline
    American City Business Journals

    Local companies impacted by trade war-fueled stock market decline

    Among the Philadelphia region’s largest 20 publicly traded companies, three in the chemical industry experienced the biggest dips in midday trading.

  • Chemours CEO addresses disappointing results
    American City Business Journals

    Chemours CEO addresses disappointing results

    Chemours also announced a $25 million acquisition of a mineral mining and manufacturing firm in Florida.

  • DuPont de Nemours Tops Analysts on Earnings
    GuruFocus.com

    DuPont de Nemours Tops Analysts on Earnings

    Revenue misses expectations Continue reading...

  • DowDuPont Inc. (DWDP) Q2 2019 Earnings Call Transcript
    Motley Fool

    DowDuPont Inc. (DWDP) Q2 2019 Earnings Call Transcript

    DWDP earnings call for the period ending June 30, 2019.

  • TheStreet.com

    Ex-DowDuPont Unit Corteva Jumps as Adjusted Profit Exceeds Estimates

    Corteva shares jumped 5.9% to $31.25 on Thursday even as it reported quarterly profit was more than halved due to costs related to the DowDuPont breakup. The Wilmington, Del., company, formerly the agricultural unit of DowDuPont, reported second-quarter net income fell to $470 million, or 63 cents a share, from $963 million, or $1.

  • DuPont's (DD) Earnings Top, Sales Trail Estimates in Q2
    Zacks

    DuPont's (DD) Earnings Top, Sales Trail Estimates in Q2

    DuPont (DD) gains from cost and pricing actions in Q2. The company raises adjusted earnings per share guidance for 2019.

  • Stocks - FitBit, Beyond Meat Fall Premarket; Verizon, General Motors Rise
    Investing.com

    Stocks - FitBit, Beyond Meat Fall Premarket; Verizon, General Motors Rise

    Investing.com - Stocks in focus in premarket trading on Thursday:

  • Benzinga

    DuPont de Nemours Reports Mixed Q2 Earnings, Raises Guidance

    DuPont de Nemours (NYSE: DD ) reported second-quarter earnings of 97 cents per share, which beat the analyst consensus estimate of 82 cents by 18.29%. This is a 29.2% decrease over earnings of $1.37 per ...

  • Reuters

    UPDATE 2-Corteva shares rise as profit beats on international markets

    Pesticide and insecticide maker Corteva Inc's quarterly profit beat estimates as volumes and prices in its international markets rose more than expected, sending its shares up more than 8%. Investors cheered Corteva's upbeat numbers, its first after separation from DowDupont in June, as they were a rare bright spot among agricultural companies that have been hard hit as floods ravaged huge swathes of western Corn Belt states. Chief Executive James Collins, on a post-earnings call with analysts, said the unprecedented market backdrop for the second quarter presented considerable challenges to Corteva's customers and in turn, to the company.

  • MarketWatch

    DuPont tops profit estimates for second quarter but sales fall short

    Materials company DuPont de Nemours Inc. said Thursday it had a net loss of $571 million, or 76 cents a share, in the second quarter, after earnings of $1.769 billion, or $2.27 a share, in the year-earlier period. Adjusted per-share earnings came to 97 cents, ahead of the 89 cents FactSet consensus. Sales fell 7% to $5.5 billion, below the FactSet consensus of $6.021 billion. "In the face of weaker than expected market conditions, our teams delivered on our bottom-line commitments by driving both cost and pricing actions resulting in operating EBITDA(1) margin improvement of 170 basis points in the quarter," Chief Executive Marc Doyle said in a statement. DuPont merged with Dow Chemical in 2015, before again breaking into separate Dow and DuPont companies, as well as spinning out its agricultural division into a company called Corteva. This quarter's numbers included goodwill impairment charges of $1.57 and an income tax charge of 22 cents a share, offset by the absence of 35 cents a share of costs associated with Dow and Corteva. The company raised its full-year pro forma adjusted EPS guidance to $3.75 to $3.85. Shares were down 3.5% premarket but have gained 5.5% in 2019, while the S&P 500 has gained 19%.

  • Barrons.com

    DuPont Just Beat Earnings Estimates. Here’s What It Means for the Stock.

    (DD) (ticker: DD) shares are down 5% year to date, worse than the 15% change of the Dow Jones Industrial Average over the same span. In the first quarter of 2019—when (DOW) (DOW) was still part of the company and (DD) was still called Dow (DD)—much of the focus for Wall Street was on China, as well as weakness in the automotive and electronics industries. DuPont management is focused on managing profit margins given this mild downturn.

  • DuPont's (DD) Q2 Earnings Beat Estimates, Revenues Miss
    Zacks

    DuPont's (DD) Q2 Earnings Beat Estimates, Revenues Miss

    DuPont's (DD) Q2 adjusted earnings of 97 cents per share topped the Zacks Consensus Estimate of 86 cents.

  • Reuters

    UPDATE 3-DuPont pins hopes on lower costs to counter trade war hit

    Industrial materials maker DuPont raised its full-year profit forecast on Thursday as it plans to cut costs to combat the impact of slowing demand in the electronic and automotive sectors due to the U.S.-China trade war. The ongoing trade war between two of the world's largest economies and weakening car and smartphone sales globally have hurt companies like DuPont that supply components to a range of industries and supply chains. DuPont, one part of conglomerate DowDupont until a split earlier this year, now expects 2019 proforma adjusted profit to range between $3.75 and $3.85 per share, compared with its prior expectation of $3.70-$3.85.

  • Jon Kemp Appointed President, DuPont Electronics & Imaging
    PR Newswire

    Jon Kemp Appointed President, DuPont Electronics & Imaging

    WILMINGTON, Del., Aug. 1, 2019 /PRNewswire/ -- DuPont announced today that Jon Kemp has been appointed President, DuPont Electronics & Imaging. "Electronics & Imaging is a significant growth opportunity for DuPont. The combination of heritage Dow and DuPont businesses established the leading global supplier of differentiated products and solutions for the electronics industry," said Marc Doyle, Chief Executive Officer of DuPont.  "We very much appreciate the work Jim Fahey has done to integrate the businesses and assure a smooth transition.